{"name":"HOOKIPA Pharma","slug":"hookipa","ticker":"HOOK","exchange":"NASDAQ","domain":"hookipapharma.com","description":"HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate","hq":"New York, NY","founded":0,"employees":"82","ceo":"Joern Aldag","sector":"Immuno-Oncology / Infectious Disease","stockPrice":1.16,"stockChange":-0.02,"stockChangePercent":-1.69,"marketCap":"$14M","metrics":{"revenue":43946000,"revenueGrowth":-94.5,"grossMargin":0,"rdSpend":68507000,"netIncome":-43503000,"cash":40276000,"dividendYield":0,"peRatio":-0.2,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"taselisib patent cliff ($0.0B at risk)","drug":"taselisib","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"vacc-4x patent cliff ($0.0B at risk)","drug":"vacc-4x","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"HOOKIPA Pharma reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical pipeline and financial position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"HOOKIPA Pharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)","summary":"HOOKIPA Pharma announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine against the SARS-CoV-2 virus.","drugName":"","sentiment":"positive"},{"date":"2023-08-21","type":"trial","headline":"HOOKIPA Pharma Announces Positive Interim Results from Phase 1/2 Clinical Trial of HCV Vaccine Candidate","summary":"HOOKIPA Pharma announced positive interim results from a Phase 1/2 clinical trial of its HCV vaccine candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNU00wWTBTUGExMUp2QzZIUlJkcWl1N2xfQlNxemN3enBsbkdRNlpGQ3RCU09FNEJETG5nU3Y0SFRYVE5vcDZraVJrRXV3X0RpeEJPNmtHTXNqUTNqQ0tPS0I5MGRPcUt5UzV2N3ZNeXRDODhsUFlTT2hPWXB3WEE4aHpjUkVaVGFGZ1lFTlI0UjNDbnZfbjg5a3FFU1N1aURuNEtvYVZ3TTdhbkNwZUVVUExuVjFSQUYxN2ZqT1U4MXRfdUg5Si1vWU1UYjRvUWlGaXFQRHo4ekdHWHZlZnlNc1lNUGFoUG84RUtNSDhYR0U?oc=5","date":"2026-03-26","type":"pipeline","source":"globenewswire.com","summary":"HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics - globenewswire.com","headline":"HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQeE9WanJjVm05SkhXbmcwWllwb2lTdk1EbHFrTk1VZDh5aFkza3U2UUZQT1Ffb3FRaTQ2S2dRNG81cGFNVVFiZkZTb0stWjJaZFNsQmw4NEFhNy1fbVJYZ0NxWFlyVjN0Z3FwRFdTTHNkUG4yWGI4b0MzcGJMWWJmQlhZeTVpZ2ZvNS1iTnU3a3FqWEtZSi1VbE04aS1mZ2dod0taX0E1V3hrcGVQYTFUZ18yTTNJMUJVSjA3ZjZxbk5PRzNyRWgwbXRsVGRhX0l5TGFXYVN6ZkZwVW5BR0Jz?oc=5","date":"2026-03-26","type":"pipeline","source":"ChartMill","summary":"HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics - ChartMill","headline":"HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZVB1UTNtNmtPQ2lLQnJmaEZkd0c0ZVUxSE5KR2NvZHNCOXlDbURXOVI4SUZsdDFUMWdPVmpoaVVZemxBRHBrS3ZiUVhJY2t3Um9DOEhzUDRyblg2V0ZKang5N0lWRUpkTzROcDc2U1dWV2Q5R2dyUDNQQkJraHlpU1BFanU1alFFTUJyWGxYTFpHcm9McE9lU3JocFVrUDE2ZlZSeElOSThkNmhtaEVXeTlvT1VEc1BqMlV1T2hCdHRhdw?oc=5","date":"2026-02-03","type":"pipeline","source":"Quiver Quantitative","summary":"HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail Therapeutics - Quiver Quantitative","headline":"HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPSEtFelRvSVdTSWxfc25mWVNCNUFQelFWajg3Zk9OM0FVVHZmRjhzTDlOdzFYR1UxdEFIUXZTX0lZXzA0UXhhczBGeGVJMnhaUlZFREcwMDROZ3RXQVRaMEpRUGhfZUFGaV9CenJwcDdzeVd2S2RPODNXNGo5d2UyakgzTmY2RGNEQjZCZlllX200Z1I5QV9ZZ0xKbFBsS3FCRml6N2tJXy15dXlkVXRxNEZDd1FRZmJ4aElLMEFHWURuOUdyYzN2YWEwdk5RMmNFRFRTclRmRTl2cUtzM3c?oc=5","date":"2026-02-03","type":"pipeline","source":"globenewswire.com","summary":"HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics - globenewswire.com","headline":"HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOTXVFMTh0NGprUUpjNEZNa3Jick9ia2lpc05waFkxdzZIc29vRUliQzZLWVFWYjFFTUtlWXhpdmJtNWJJTHR4OU44UmlnNFZvdGt0ampaX0xfWHMzRnU4SjFpRkI3aTNUZWFJS1RKMTRfbkxXWElPbWJqeUJGWmFZRVVvZ2hQeWtmbG5fNDhpWS1IcjZpd1ctNmtsQ0MtNzlRVmh3T0dWLWI3OG9pWHdxVjk5aGtvYXQ3TjBISldESUxPRTlPX3J4T3lnQ1V5aGxyVlhKMXQ2RHR1cElULXdsTA?oc=5","date":"2025-10-31","type":"pipeline","source":"globenewswire.com","summary":"HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - globenewswire.com","headline":"HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-09","type":"pipeline","source":"MSN","summary":"HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale - MSN","headline":"HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1zMU1NLWk0ejd0aGJGS0Q0VHc0WHg1WlZEN0x1RDVSdHByOVVlbHk5Snd6Rm85YmJPVWNOc1k5RkpGQ3JoXzNHWGRTajJSR0hXRlNQZ2tCRlk?oc=5","date":"2025-08-09","type":"pipeline","source":"TradingView","summary":"HOOK Stock Price and Chart — OTC:HOOK - TradingView","headline":"HOOK Stock Price and Chart — OTC:HOOK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ManM2X3lyRFRJS01wY2ZrTW9Cc0U1bWxUYmNZVmZ2dE80YXZzcmtxYVVFUk9oc3hnWVg2NTk0UWRTanpYQU9xUTcyTS1MekR5UE8yX0xIYUN3RVJ1eHBj?oc=5","date":"2025-08-07","type":"pipeline","source":"ChartMill","summary":"HOOK Stock Price, Quote & Chart | HOOKIPA PHARMA INC (NASDAQ:HOOK) - ChartMill","headline":"HOOK Stock Price, Quote & Chart | HOOKIPA PHARMA INC (NASDAQ:HOOK)","sentiment":"neutral"},{"date":"2025-07-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNbHl2SEpKdjVwR0RBYjlaTFBkMW9KTUZCLWJ4V0trWTFiODU1eEpPdkg3T1pQb21FR0otUnhQc0hMN1l0UC16UWxVMFVMU2JJYjQ5c2l2eldhbWxjemIzM2xvMGNCSVlBWFJOZC1pVERWNElzaVh2bDlCaFJDYkIzeW1QOWt0Z0hGaU5oTjBXUm5IOVhTZ201YTJibWtfTGp4VUFGLUxFWHBySk1oWXNoeFQ3dDFkaUsyazhwR2ZiQmIxRDVCZkRBQ05rajhXWkNUWUZUMg?oc=5","date":"2025-07-19","type":"pipeline","source":"The Globe and Mail","summary":"Hookipa Pharma to Delist from Nasdaq Amid Asset Sale - The Globe and Mail","headline":"Hookipa Pharma to Delist from Nasdaq Amid Asset Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNTWdianFaR2RldExVQXFzczVmV0kyVngxN1dJako1SDhIM1JsV0tMRlVwbUVxQU8tOWNKQ1FPV2MzUlhBMjItYmZUZ3F6U2w4OW83WHNFZjR6dmdUbTJBajhZM2JxRkNfLXBDZUp6R2N5VS1JYUhPY2JRbE5ZM3hoZWlCMXdnTDEzQ2VGeXhSaUdqNVBVX1B3?oc=5","date":"2025-07-18","type":"pipeline","source":"Yahoo Finance","summary":"HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock - Yahoo Finance","headline":"HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock","sentiment":"neutral"},{"date":"2025-07-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOSTZUM0ZwSktwel9ITldxUzdNZFNnYTJrOWpyUFFtRHBDeWt2SnFCbGRrcDFUZG02Y0NVMmFvMkZlNlI1T1pUckRuWjhMZTY1Ynd5S0NhcUszWWVnM0NoSHRHQzc4MXhNWThpQUlwbVFSTVJIdkhyQ05QUHNJMFFNNy1EUUw1NnExeFotM1BkckVDZjg?oc=5","date":"2025-02-20","type":"deal","source":"Fierce Biotech","summary":"UPDATE: US biotech Hookipa retracts merger plans with UK company - Fierce Biotech","headline":"UPDATE: US biotech Hookipa retracts merger plans with UK company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNcXBXeHNvYTIxQlhDMXFFSGwya3VXWFk3SGtwSl9pLVIwX0dBT1JzS28wcTVmMXJQejBWLTFnR1Q2MWVZSFUxTzctbDhWQ3JmUG1ta3B6YWJFQ0JOVVNNRnBOaTRkQ01sZzJVUlpEUGNpZWpZbGxfVk1saUF0bmNHUVkzdFRzMjBhNGY4ZGhIMncyRVI1N0ZweFRfb3RFeG9fRG1kWjEwbk5TaFJQdHNOVVBwcnJoM3N3LVU4V0tDWER6dkVpWk9B?oc=5","date":"2023-11-21","type":"regulatory","source":"European AIDS Treatment Group","summary":"HOOKIPA Pharma announces FDA clearance of its IND application for HB-500 for the treatment of HIV - European AIDS Treatment Group","headline":"HOOKIPA Pharma announces FDA clearance of its IND application for HB-500 for the treatment of HIV","sentiment":"neutral"}],"patents":[{"drugName":"taselisib","drugSlug":"taselisib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"vacc-4x","drugSlug":"vacc-4x","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BioNTech","Moderna Therapeutics","Incyte Corporation"],"therapeuticFocus":["Infectious Diseases","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":43946000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":43946000,"period":"2024-12-31"},{"value":20129000,"period":"2023-12-31"},{"value":20129000,"period":"2023-12-31"},{"value":14249000,"period":"2022-12-31"},{"value":14249000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":68507000,"rdSpendHistory":[{"period":"2024-12-31","value":68507000},{"period":"2023-12-31","value":86424000},{"period":"2022-12-31","value":68645000},{"period":"2021-12-31","value":82853000}],"sgaSpend":20226000,"operatingIncome":-37391000,"operatingIncomeHistory":[{"period":"2024-12-31","value":-37391000},{"period":"2023-12-31","value":-73735000},{"period":"2022-12-31","value":-65239000},{"period":"2021-12-31","value":-71950000}],"netIncome":-43503000,"netIncomeHistory":[{"period":"2024-12-31","value":-43503000},{"period":"2023-12-31","value":-81580000},{"period":"2022-12-31","value":-64915000},{"period":"2021-12-31","value":-75665000}],"eps":-3.47,"epsHistory":[{"period":"2024-12-31","value":-3.47},{"period":"2023-12-31","value":-8.63},{"period":"2022-12-31","value":-9.9},{"period":"2021-12-31","value":-23}],"cash":39684000,"cashHistory":[{"period":"2024-12-31","value":39684000},{"period":"2023-12-31","value":117096000},{"period":"2022-12-31","value":112488000},{"period":"2021-12-31","value":65921000}],"totalAssets":82545000,"totalLiabilities":31331000,"totalDebt":875000,"equity":51214000,"operatingCashflow":-76978000,"operatingCashflowHistory":[{"period":"2024-12-31","value":-76978000},{"period":"2023-12-31","value":-57524000},{"period":"2022-12-31","value":-19997000},{"period":"2021-12-31","value":-66016000}],"capex":-194000,"capexHistory":[{"period":"2024-12-31","value":-194000},{"period":"2023-12-31","value":-4159000},{"period":"2022-12-31","value":-5017000},{"period":"2021-12-31","value":-12581000}],"freeCashflow":-77172000,"dividendsPaid":null,"buybacks":null,"employees":82,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4540000,"ebit":-1786000,"ebitda":-1322000,"period":"2025-06-30","revenue":6795000,"epsBasic":-0.4,"netIncome":-1786000,"rdExpense":8926000,"epsDiluted":-0.4,"grossProfit":null,"operatingIncome":-6512000},{"sga":6886000,"ebit":-15427000,"ebitda":-15038000,"period":"2025-03-31","revenue":2004000,"epsBasic":-1.23,"netIncome":-15427000,"rdExpense":12859000,"epsDiluted":-1.23,"grossProfit":null,"operatingIncome":-17514000},{"sga":5493000,"ebit":-25056000,"ebitda":-24357000,"period":"2024-12-31","revenue":1354000,"epsBasic":null,"netIncome":-24950000,"rdExpense":13025000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-16692000},{"sga":6732000,"ebit":-13841000,"ebitda":-13141000,"period":"2024-09-30","revenue":4703000,"epsBasic":-1.1,"netIncome":-13841000,"rdExpense":15565000,"epsDiluted":-1.1,"grossProfit":null,"operatingIncome":-15411000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.16,"previousClose":1.18,"fiftyTwoWeekHigh":1.77,"fiftyTwoWeekLow":0.81,"fiftyTwoWeekRange":"0.811 - 1.77","fiftyDayAverage":1.12,"twoHundredDayAverage":0.97,"beta":0.83,"enterpriseValue":-24725418,"forwardPE":-0.2,"priceToBook":0.43,"priceToSales":1.54,"enterpriseToRevenue":-2.64,"enterpriseToEbitda":0.34,"pegRatio":0,"ebitda":-72401000,"ebitdaMargin":0,"freeCashflow":-32811376,"operatingCashflow":-52770000,"totalDebt":596000,"debtToEquity":1.7,"currentRatio":3.61,"returnOnAssets":-45.2,"returnOnEquity":-105.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":3.2,"sharesOutstanding":9976985,"floatShares":12341458,"sharesShort":35804,"shortRatio":0.57,"shortPercentOfFloat":0.3,"epsTrailing":-4.83,"epsForward":-5.43,"revenuePerShare":0.75,"bookValue":2.71,"officers":[{"age":63,"name":"Dr. Malte  Peters M.D.","title":"CEO, President & Director"},{"age":62,"name":"Ms. Mary Theresa Coelho M.B.A.","title":"Executive VP, CFO & Director"},{"age":50,"name":"Dr. Daniel D. Pinschewer M.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":39,"name":"Dr. Mark  Winderlich Ph.D.","title":"Chief Research & Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.hookipapharma.com","phone":"431 890 6360"}}